Search Results - "Craig, Alexander F M"

Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA by Kurtz, David M., Soo, Joanne, Co Ting Keh, Lyron, Alig, Stefan, Chabon, Jacob J., Sworder, Brian J., Schultz, Andre, Jin, Michael C., Scherer, Florian, Garofalo, Andrea, Macaulay, Charles W., Hamilton, Emily G., Chen, Binbin, Olsen, Mari, Schroers-Martin, Joseph G., Craig, Alexander F. M., Moding, Everett J., Esfahani, Mohammad S., Liu, Chih Long, Dührsen, Ulrich, Hüttmann, Andreas, Casasnovas, René-Olivier, Westin, Jason R., Roschewski, Mark, Wilson, Wyndham H., Gaidano, Gianluca, Rossi, Davide, Diehn, Maximilian, Alizadeh, Ash A.

“…Circulating tumor-derived DNA (ctDNA) is an emerging biomarker for many cancers, but the limited sensitivity of current detection methods reduces its utility…”
Get full text

Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA by Scherer, Florian, Kurtz, David M, Newman, Aaron M, Stehr, Henning, Craig, Alexander F M, Esfahani, Mohammad Shahrokh, Lovejoy, Alexander F, Chabon, Jacob J, Klass, Daniel M, Liu, Chih Long, Zhou, Li, Glover, Cynthia, Visser, Brendan C, Poultsides, George A, Advani, Ranjana H, Maeda, Lauren S, Gupta, Neel K, Levy, Ronald, Ohgami, Robert S, Kunder, Christian A, Diehn, Maximilian, Alizadeh, Ash A

“…Patients with diffuse large B cell lymphoma (DLBCL) exhibit marked diversity in tumor behavior and outcomes, yet the identification of poor-risk groups remains…”
Get more information

Liquid biopsy in lymphoma: Molecular methods and clinical applications by Cirillo, Melita, Craig, Alexander F.M., Borchmann, Sven, Kurtz, David M.

“…•Can detect small amounts of circulating tumor DNA from a single blood test.•Emerges as a viable method of tumor genotyping in most lymphoma subtypes.•Has the…”
Get full text

Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma by Kurtz, David M, Scherer, Florian, Jin, Michael C, Soo, Joanne, Craig, Alexander F M, Esfahani, Mohammad Shahrokh, Chabon, Jacob J, Stehr, Henning, Liu, Chih Long, Tibshirani, Robert, Maeda, Lauren S, Gupta, Neel K, Khodadoust, Michael S, Advani, Ranjana H, Levy, Ronald, Newman, Aaron M, Dührsen, Ulrich, Hüttmann, Andreas, Meignan, Michel, Casasnovas, René-Olivier, Westin, Jason R, Roschewski, Mark, Wilson, Wyndham H, Gaidano, Gianluca, Rossi, Davide, Diehn, Maximilian, Alizadeh, Ash A

“…Outcomes for patients with diffuse large B-cell lymphoma remain heterogeneous, with existing methods failing to consistently predict treatment failure. We…”
Get full text

Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas by Sworder, Brian J., Kurtz, David M., Alig, Stefan K., Frank, Matthew J., Shukla, Navika, Garofalo, Andrea, Macaulay, Charles W., Shahrokh Esfahani, Mohammad, Olsen, Mari N., Hamilton, James, Hosoya, Hitomi, Hamilton, Mark, Spiegel, Jay Y., Baird, John H., Sugio, Takeshi, Carleton, Mia, Craig, Alexander F.M., Younes, Sheren F., Sahaf, Bita, Sheybani, Natasha D., Schroers-Martin, Joseph G., Liu, Chih Long, Oak, Jean S., Jin, Michael C., Beygi, Sara, Hüttmann, Andreas, Hanoun, Christine, Dührsen, Ulrich, Westin, Jason R., Khodadoust, Michael S., Natkunam, Yasodha, Majzner, Robbie G., Mackall, Crystal L., Diehn, Maximilian, Miklos, David B., Alizadeh, Ash A.

“…Most relapsed/refractory large B cell lymphoma (r/rLBCL) patients receiving anti-CD19 chimeric antigen receptor (CAR19) T cells relapse. To characterize…”
Get full text

Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma by Alig, Stefan, Macaulay, Charles W, Kurtz, David M, Dührsen, Ulrich, Hüttmann, Andreas, Schmitz, Christine, Jin, Michael C, Sworder, Brian J, Garofalo, Andrea, Shahrokh Esfahani, Mohammad, Nabet, Barzin Y, Soo, Joanne, Scherer, Florian, Craig, Alexander F M, Casasnovas, Olivier, Westin, Jason R, Gaidano, Gianluca, Rossi, Davide, Roschewski, Mark, Wilson, Wyndham H, Meignan, Michel, Diehn, Maximilian, Alizadeh, Ash A

“…Patients with Diffuse Large B-cell Lymphoma (DLBCL) in need of immediate therapy are largely under-represented in clinical trials. The diagnosis-to-treatment…”
Get full text

A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL by Cherng, Hua-Jay J., Alig, Stefan K., Oki, Yasuhiro, Nastoupil, Loretta J., Fayad, Luis, Neelapu, Sattva S., Turturro, Francesco, Hagemeister, Fredrick, Craig, Alexander F. M., Macaulay, Charles W., Rodriguez, Maria Alma, Lee, Hun Ju, McDonnell, Timothy J., Flowers, Christopher R., Vega, Francisco, Green, Michael R., Feng, Lei, Kurtz, David M., Alizadeh, Ash A., Davis, R. Eric, Westin, Jason R.

“…•Lenalidomide, obintuzumab, and CHOP chemotherapy are efficacious and well tolerated treatments for newly diagnosed DLBCL.•LO-CHOP led to high molecular…”
Get full text

Phased Variant Enrichment for Enhanced Minimal Residual Disease Detection from Cell-Free DNA by Kurtz, David M., Soo, Joanne, Alig, Stefan, Keh, Lyron Co Ting, Macaulay, Charles, Jin, Michael C., Scherer, Florian, Hamilton, Emily G., Liu, Chih Long, Chen, Binbin, Craig, Alexander F.M., Diehn, Maximilian, Alizadeh, Ash A.

“…Background: Circulating tumor DNA (ctDNA) is an emerging biomarker in non-Hodgkin lymphomas (NHLs). Current methods for ctDNA minimal residual disease (MRD)…”
Get full text

Towards Non-Invasive Classification of DLBCL Genetic Subtypes By Ctdna Profiling by Esfahani, Mohammad Shahrokh, Alig, Stefan, Kurtz, David M., Soo, Joanne, Jin, Michael C., Macaulay, Charles, Craig, Alexander F.M., Garofalo, Andrea, Steen, Chloe B., Scherer, Florian, Sworder, Brian, Diehn, Maximilian, Alizadeh, Ash A.

“…Background Diffuse large B-cell lymphoma (DLBCL) is a genetically and clinically heterogeneous disease. The cell-of-origin (COO) classification subdivides…”
Get full text

Profiling T-Cell Receptor Diversity and Dynamics during Lymphoma Immunotherapy Using Cell-Free DNA (cfDNA) by Shukla, Navika D, Craig, Alexander F.M., Sworder, Brian, Kurtz, David M., Macaulay, Charles, Garofalo, Andrea, Frank, Matthew J., Alig, Stefan, Duran, George, Kim, Youn H., Zehnder, James, Mackall, Crystal L., Miklos, David B., Diehn, Maximilian, Khodadoust, Michael S., Alizadeh, Ash A.

“…Background: Characterization of T-cell receptor (TCR) diversity and dynamics is increasingly critical to understanding therapeutic immune responses targeting…”
Get full text

Bendamustine, Obinutuzumab and Venetoclax As Induction Therapy for Untreated Mantle Cell Lymphoma by Greenwell, Irl Brian, Switchenko, Jeffrey M., Maddocks, Kami J., Kahl, Brad S., Craig, Alexander F.M., Alizadeh, Ash A., Allen, Pamela B., Marbury, Alena Lorretta, Escobar, Alicia, Valla, Kelly, Williams, Miayea, Parikh, Priya, Roberts, Danielle, Neely, Jessica J., Palmer, Alexandra, Blum, Kristie A., Cohen, Jonathon B.

“…Bendamustine-rituximab (BR) is a standard of care for patients with mantle cell lymphoma (MCL) with median progression free survival (PFS) of approximately 3…”
Get full text

Reply to J. Wang et al by Kurtz, David M, Scherer, Florian, Jin, Michael C, Soo, Joanne, Craig, Alexander F M, Esfahani, Mohammad S, Chabon, Jacob J, Stehr, Henning, Liu, Chih Long, Tibshirani, Robert, Maeda, Lauren S, Gupta, Neel K, Khodadoust, Michael S, Advani, Ranjana H, Newman, Aaron M, Dührsen, Ulrich, Hüttmann, Andreas, Meignan, Michel, Casasnovas, Olivier, Westin, Jason R, Roschewski, Mark, Wilson, Wyndham H, Gaidano, Gianluca, Rossi, Davide, Diehn, Maximilian, Alizadeh, Ash A

Get full text